Fibroblast growth factor-2 and periodontal regeneration: a systematic review and meta-analysis

Fibroblast Growth Factor-2 (FGF-2), due to its key role in promoting angiogenesis, fibroblast proliferation, and differentiation of periodontal stem cells, has attracted attention as an adjunctive agent in periodontal regeneration. This study aims to conduct a systematic review to assess the effect of FGF-2 on clinical and radiographic parameters of periodontal defect regeneration. An electronic search was conducted in the PubMed, Scopus, and Web of Science databases, up to June 2025. The full texts of the articles were reviewed. Studies that evaluated the effect of FGF-2 on the treatment of periodontal intrabony defects were included. Risk of Bias was assessed using the revised Cochrane risk of bias tool for randomized trials (RoB 2). A random-effects model was used for meta-analysis. In total, nine clinical trials were included, from which seven were analyzed. Meta-analysis of the clinical trials showed that the Placebo (Carrier-alone Group), compared to FGF-2 + carrier, significantly increased bone level gain at 6 months and 9 months post-operation ( P < 0.001). However, reductions in Clinical Attachment Loss (CAL) and Pocket Depth (PD) were not statistically significant at any time point. Regarding the absolute effect of FGF-2 + carrier after 6 months, a bone level gain of 25.08% (95% CI: 20.01–30.15), CAL reduction of 2.42 mm (95% CI: 2.08–2.76), and PD reduction of 3.06 mm (95% CI: 2.76–3.36) were observed. According to the GRADE approach, certainty of evidence was high for CAL reduction at all follow-ups, while bone level gain showed low certainty at 3 and 9 months and moderate certainty at 6 months due to heterogeneity and imprecision. The use of FGF-2 in the treatment of periodontal defects can play an effective role in promoting bone level gain and reducing CAL and PD.

Authors

Institutions

Publication Details

Journal
BMC Oral Health
Published
2026-11-14
DOI
https://doi.org/10.1186/s12903-026-10443-x
Primary Topic
Periodontal Regeneration and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Fibroblast growth factor-2 and periodontal regeneration: a systematic review and meta-analysis

Ali Azadi, Zahra Baghani, Nozhan Azimi, Fazele Atarbashi‐Moghadam et al.
BMC Oral Health
Periodontal Regeneration and Treatments
article

Fibroblast growth factor-2 and periodontal regeneration: a systematic review and meta-analysis

Ali Azadi, Zahra Baghani, Nozhan Azimi, Fazele Atarbashi‐Moghadam, Ali Ghased
article en

Abstract

Fibroblast Growth Factor-2 (FGF-2), due to its key role in promoting angiogenesis, fibroblast proliferation, and differentiation of periodontal stem cells, has attracted attention as an adjunctive agent in periodontal regeneration. This study aims to conduct a systematic review to assess the effect of FGF-2 on clinical and radiographic parameters of periodontal defect regeneration. An electronic search was conducted in the PubMed, Scopus, and Web of Science databases, up to June 2025. The full texts of the articles were reviewed. Studies that evaluated the effect of FGF-2 on the treatment of periodontal intrabony defects were included. Risk of Bias was assessed using the revised Cochrane risk of bias tool for randomized trials (RoB 2). A random-effects model was used for meta-analysis. In total, nine clinical trials were included, from which seven were analyzed. Meta-analysis of the clinical trials showed that the Placebo (Carrier-alone Group), compared to FGF-2 + carrier, significantly increased bone level gain at 6 months and 9 months post-operation ( P < 0.001). However, reductions in Clinical Attachment Loss (CAL) and Pocket Depth (PD) were not statistically significant at any time point. Regarding the absolute effect of FGF-2 + carrier after 6 months, a bone level gain of 25.08% (95% CI: 20.01–30.15), CAL reduction of 2.42 mm (95% CI: 2.08–2.76), and PD reduction of 3.06 mm (95% CI: 2.76–3.36) were observed. According to the GRADE approach, certainty of evidence was high for CAL reduction at all follow-ups, while bone level gain showed low certainty at 3 and 9 months and moderate certainty at 6 months due to heterogeneity and imprecision. The use of FGF-2 in the treatment of periodontal defects can play an effective role in promoting bone level gain and reducing CAL and PD.

BMC Oral Health
Research Institute for Endocrine Sciences (IR), Sabzevar University of Medical Sciences (IR), Shahid Beheshti University (IR), Shahid Beheshti University of Medical Sciences (IR)
Periodontal Regeneration and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon